Global Drugs for Vulvovaginal Candidiasis (VVC) Market Size, By Formulation Type (Topical (Cream, Lotion, Gel, Ointment, Aerosol, Foam, Powder, Solution etc.), Pessary (Suppositories, Kit), and Oral (Tablet, Capsule, Powder for Suspension etc.)), By Drug Types (Miconazole, Clotrimazole, Fluconazole, Econazole, and Others (Itraconazole, Nystatin, Tioconazole, amphotericin B Etc.)), and By End User (Hospital, Clinic, and Pharmacy), and By Region (North America, Europe, Asia Pacific, Middle East & Africa and Latin America); Trend Analysis, Competitive Market Share & Forecast, 2016-26
Published:
February 2020
Report Code:
BWC19400
Available Format:
PDF PDF Icon
Pages:
180

drugs for vulvovaginal candidiasis (vvc) market bwc19400

1.    Research Framework

1.1. Research Objective

1.2. Product Overview

1.3. Market Segmentation

2.    Research Methodology

2.1. Qualitative Research

2.1.1.   Primary & Secondary Sources

2.2. Quantitative Research

2.2.1.   Primary & Secondary Sources

2.3. Breakdown of Primary Research Respondents, By Region

2.3.1.   Secondary Research

2.3.2.   Primary Research

2.4. Breakdown of Primary Research Respondents

2.5. Market Size Estimation

2.6. Assumption for the Study

2.7. Market Breakdown & Data Triangulation

3.    Global Drugs for Vulvovaginal Candidiasis (VVC) Market Industry Insights

3.1. DROC Analysis

3.1.1.   Growth Drivers

3.1.2.   Restraints

3.1.3.   Opportunities

3.1.4.   Challenges

3.2. Technological Landscape

3.3. Regulatory Framework

3.4. Company market share analysis, 2019

3.5. Porter’s Five forces analysis

3.5.1.   Bargaining Power of Suppliers

3.5.2.   Bargaining Power of Buyers

3.5.3.   Threat of New Entrants

3.5.4.   Threat of Substitutes

3.5.5.   Intensity of Rivalry

4.    Global Drugs for Vulvovaginal Candidiasis (VVC) Market Overview

4.1. Market Size & Forecast 2016-2026

4.1.1.   By Value (USD) 

4.2. Market Share & Forecast

4.2.1.   By Formulation Type

4.2.1.1.       Topical (Cream, Lotion, Gel, Ointment, Aerosol, Foam, Powder, Solution etc.)

4.2.1.2.       Pessary (Suppositories, Kit)

4.2.1.3.       Oral (Tablet, Capsule, Powder for Suspension etc.)

4.2.2.   By Drug Type

4.2.2.1.       Miconazole

4.2.2.2.       Clotrimazole

4.2.2.3.       Fluconazole

4.2.2.4.       Econazole

4.2.2.5.       Others (Itraconazole, Nystatin, Tioconazole, amphotericin B Etc.)

4.2.3.   By End User

4.2.3.1.       Hospital

4.2.3.2.       Clinic

4.2.3.3.       Pharmacy

4.2.4.   By Region

4.2.4.1.       North America

4.2.4.2.       Europe

4.2.4.3.       Asia Pacific

4.2.4.4.       Latin America

4.2.4.5.       Middle East & Africa

5.    North America Drugs for Vulvovaginal Candidiasis (VVC) Market

5.1. Market estimates & forecast

5.1.1.   By Formulation Type

5.1.2.   By Drug Type

5.1.3.   By End user

5.1.4.   By Country

5.1.4.1.       U.S

5.1.4.2.       Canada

6.    Europe Drugs for Vulvovaginal Candidiasis (VVC) Market

6.1. Market estimates & forecast

6.1.1.   By Formulation Type

6.1.2.   By Drug Type

6.1.3.   By End user

6.1.4.   By Country

6.1.4.1.       Germany

6.1.4.2.       U.K

6.1.4.3.       France

6.1.4.4.       Italy

6.1.4.5.       Rest of Europe

7.    Asia Pacific Drugs for Vulvovaginal Candidiasis (VVC) Market

7.1. Market estimates & forecast

7.1.1.   By Formulation Type

7.1.2.   By Drug Type

7.1.3.   By End user

7.1.4.   By Country

7.1.4.1.       China

7.1.4.2.       India

7.1.4.3.       Japan

7.1.4.4.       Rest of APAC

8.    Latin America Drugs for Vulvovaginal Candidiasis (VVC) Market

8.1. Market estimates & forecast

8.1.1.   By Formulation Type

8.1.2.   By Drug Type

8.1.3.   By End user

8.1.4.   By Country

8.1.4.1.       Brazil

8.1.4.2.       Argentina

8.1.4.3.       Rest of Latin America

9.    Middle East & Africa Drugs for Vulvovaginal Candidiasis (VVC) Market

9.1. Market estimates & forecast

9.1.1.   By Formulation Type

9.1.2.   By Drug Type

9.1.3.   By End user

9.1.4.   By Country

9.1.4.1.       Saudi Arabia

9.1.4.2.       UAE

9.1.4.3.       South Africa

9.1.4.4.       Rest of MEA

10.Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook) *

10.1.             Bayer

10.2.             Perrigo

10.3.             J & J

10.4.             Pfizer

10.5.             Bristol-Myers Squibb

10.6.             Effik

10.7.             Teva

10.8.             Sanofi

10.9.             Cisen Pharmaceutical

10.10.          Kingyork Group

10.11.          Janssen

10.12.          Actavis

10.13.          Tianjin Kingyork Group

10.14.          Tianjin Pacific Pharmaceutical

10.15.          Lunan Pharmaceutical

10.16.          Viamet Pharmaceuticals

10.17.          Other Prominent Players

 

* Financial information of non-listed Companies will be provided as per availability

**The segmentation and the companies are subjected to modifications based on in-depth secondary for the final deliverable

WHY CHOOSE US

  • 24/7 Research support

    Get your queries resolved from an industry expert. Request for a free product review before report purchase.

  • Coustom Research Service

    Ask the Analyst to customize an exclusive study to serve your research needs.

  • Quality & Accuracy

    offers best quality reports based on various authentic and accurate data findings.

  • Data Visualization

    As the business world is changing dynamically every day. We need to stay pin point in relation to data management and optimum data utilization

  • Information security

    We never share your personal and confidential information. Your personal information is safe and secure with us.